Shun Lü
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 236
- Lung Cancer Diagnosis and Treatment 71
- Gastric Cancer Management and Outcomes 24
- Oncology 193
- Cancer Immunotherapy and Biomarkers 65
- Lung Cancer Research Studies 59
- Colorectal Cancer Treatments and Studies 45
- HER2/EGFR in Cancer Research 22
- Co-authors
- Yi‐Long Wu (54 shared papers)Caicun Zhou (17 shared papers)Chengping Hu (16 shared papers)Wěi Li (11 shared papers)Jifeng Feng (12 shared papers)Yongfeng Yu (47 shared papers)Mei Hou (6 shared papers)Chong‐Rui Xu (4 shared papers)
- Journals
- Journal of Clinical Oncology (65 papers)Annals of Oncology (52 papers)Journal of Thoracic Oncology (50 papers)Lung Cancer (19 papers)Cancer Research (14 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Shun Lü
417 papers receiving 11.3k citations
Shun Lü's Hit Papers
Peers
Comparison fields: 5 of 171
- Pulmonary and Respiratory Medicine 6.2k
- Oncology 4.9k
- Cancer Research 1.5k
- Molecular Biology 2.9k
- Tourism, Leisure and Hospitality Management 60
Countries citing papers authored by Shun Lü
This map shows the geographic impact of Shun Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shun Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shun Lü more than expected).
Fields of papers citing papers by Shun Lü
This network shows the impact of papers produced by Shun Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shun Lü. The network helps show where Shun Lü may publish in the future.
Co-authors
The 25 scholars most cited alongside Shun Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 442 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 1608 |
| 2 | The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC Hit paper breakdown → | 2019 | 422 |
| 3 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Hit paper breakdown → | 2017 | 406 |
| 4 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial Hit paper breakdown → | 2015 | 337 |
| 5 | Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC Hit paper breakdown → | 2023 | 300 |
| 6 | BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 285 |
| 7 | 2019 | 267 | |
| 8 | Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 264 |
| 9 | 2018 | 232 | |
| 10 | 1995 | 226 | |
| 11 | 2018 | 214 | |
| 12 | 2012 | 198 | |
| 13 | 2012 | 185 | |
| 14 | 2021 | 152 | |
| 15 | 2018 | 142 | |
| 16 | 2018 | 139 | |
| 17 | 2020 | 112 | |
| 18 | 2013 | 95 | |
| 19 | 2019 | 94 | |
| 20 | 2014 | 92 |
About Shun Lü
Shun Lü is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 442 papers that have together received 11.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (236 papers), Lung Cancer Diagnosis and Treatment (71 papers), Cancer Immunotherapy and Biomarkers (65 papers), Lung Cancer Research Studies (59 papers), Colorectal Cancer Treatments and Studies (45 papers), Cancer Genomics and Diagnostics (30 papers), Gastric Cancer Management and Outcomes (24 papers) and HER2/EGFR in Cancer Research (22 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (6.2k citations), Oncology (4.9k citations), Cancer Research (1.5k citations), Molecular Biology (2.9k citations) and Tourism, Leisure and Hospitality Management (60 citations). Shun Lü has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Yi‐Long Wu, Caicun Zhou, Chengping Hu, Wěi Li, Jifeng Feng, Yongfeng Yu, Mei Hou, Chong‐Rui Xu, Dan Massey and Jian Hua Shi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.